About Us
Our Company
Our People
Our Science
Our Science
Precise Antibody Engineering
Cytokine-Fusion Antibody
Novel T cell Targets
Pipeline
Pipeline
MMB101
MMB102
MFA011
Partnering
News
About Us
Our Company
Our People
Our Science
Our Science
Precise Antibody Engineering
Cytokine-Fusion Antibody
Novel T cell Targets
Pipeline
Pipeline
MMB101
MMB102
MFA011
Partnering
News
About us
Our Company
Our People
Contact
Home
Our Science
Cytokine-Fusion Antibody
Novel T cell Targets
Precise Antibody Engineering
Partnering with Us
Pipeline
MFA011
MMB101
MMB102
News
2024-04-30
MediMabBio, a MoU signing with PDC*line Pharma to collaborate on cancer im munotherapy
2024-01-30
MediMabBio Selected for Celltrion’s Open Innovation Program
2022-01-01
MediMabBio selected as the ‘Best Employer’ by Seongnam City Council
2021-10-28
MediMabBio takes first step towards commercialization with Thermo Fisher CDMO Contract
2021-06-28
MediMabBio has made a collaboration deal with University Hospitals Birmingham for immunotherapy cancer drug development
2021-02-15
MediMabBio has successfully completed a Series-A fundraising with 18 million USD
2020-05-27
MediMabBio establishes UK Subsidiary, MediMab Biotherapeutics
2019-02-19
MediMabBio Secures $3 Million Investment to Advance “New-Generation Cancer Treatment”
2017-07-26
MediMabBio Chosen for Up to $1 Million Funding from the TIPS Program